Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Aridis Pharmaceuticals Inc (ARDS)

Aridis Pharmaceuticals Inc (ARDS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 48,476
  • Shares Outstanding, K 12,119
  • Annual Sales, $ 1,000 K
  • Annual Income, $ -22,330 K
  • 60-Month Beta 0.11
  • Price/Sales 48.48
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade ARDS with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.48
  • Number of Estimates 2
  • High Estimate -0.42
  • Low Estimate -0.54
  • Prior Year -0.65
  • Growth Rate Est. (year over year) +26.15%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.54 +8.90%
on 08/20/21
4.34 -11.29%
on 09/03/21
-0.15 (-3.75%)
since 08/16/21
3-Month
3.54 +8.90%
on 08/20/21
7.72 -50.13%
on 06/29/21
-2.97 (-43.55%)
since 06/16/21
52-Week
3.54 +8.90%
on 08/20/21
8.50 -54.71%
on 10/22/20
-3.54 (-47.90%)
since 09/16/20

Most Recent Stories

More News
ARIDIS PHARMACT (ARDS) Reports Q2 Loss, Misses Revenue Estimates

ARIDIS PHARMACT (ARDS) delivered earnings and revenue surprises of 3.51% and -91.75%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

ARDS : 3.81 (-4.75%)
Aridis Pharmaceuticals Announces Second Quarter 2021 Results

/PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections,...

ARDS : 3.81 (-4.75%)
Analysts Estimate ARIDIS PHARMACT (ARDS) to Report a Decline in Earnings: What to Look Out for

ARIDIS PHARMACT (ARDS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ARDS : 3.81 (-4.75%)
Aridis Pharmaceuticals Announces $25 Million Registered Direct Offering Priced at a Premium to Market

/PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections,...

ARDS : 3.81 (-4.75%)
Aridis Pharmaceuticals' COVID mAb Ranks Among the Top 5 Most Potent COVID-19 mAbs Evaluated by the Coronavirus Immunotherapeutics Consortium (CoVIC)

/PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections,...

ARDS : 3.81 (-4.75%)
Aridis Pharmaceuticals Announces Exclusive License of Suvratoxumab, a Phase 3-Ready Monoclonal Antibody, from AstraZeneca

/PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) today announced that it has entered into an exclusive, worldwide licensing agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) to in-license the...

AZN.LN : 8,141.000 (+0.20%)
AZN : 56.69 (+0.43%)
ARDS : 3.81 (-4.75%)
Aridis' (ARDS) COVID Antibody Combo Neutralizes Delta Variant

Aridis Pharmaceuticals' (ARDS) inhaled COVID-19 dual antibody cocktail treatment, AR-712, binds and neutralizes the Delta variant of the virus. Stock rises in after-hours trading.

REGN : 655.39 (+0.52%)
LLY : 231.39 (-1.00%)
ARDS : 3.81 (-4.75%)
VIR : 52.60 (+0.55%)
Aridis Pharmaceuticals COVID mAb AR-712 Neutralizes SARS-CoV-2 Delta Variant

/PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections,...

ARDS : 3.81 (-4.75%)
Strength Seen in ARIDIS PHARMACT (ARDS): Can Its 10% Jump Turn into More Strength?

ARIDIS PHARMACT (ARDS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength...

ARDS : 3.81 (-4.75%)
Aridis Pharmaceuticals Announces First Quarter 2021 Results

, /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections,...

ARDS : 3.81 (-4.75%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Aridis Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the discovery and development of immunotherapy using fully human monoclonal antibodies to treat life-threatening infections. The company's product pipeline consists of AR-301, AR-105, AR-101, AR-401, AR-201 and AR-501 which are...

See More

Key Turning Points

3rd Resistance Point 4.27
2nd Resistance Point 4.19
1st Resistance Point 4.10
Last Price 3.81
1st Support Level 3.92
2nd Support Level 3.83
3rd Support Level 3.74

See More

52-Week High 8.50
Fibonacci 61.8% 6.60
Fibonacci 50% 6.02
Fibonacci 38.2% 5.43
Last Price 3.81
52-Week Low 3.54

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar